(Q48372101)

11 February 2018

title

A non-comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson's disease (English)

1 reference

11 February 2018

author

Ubaldo Bonuccelli

1

1 reference

11 February 2018

Giovanni Fabbrini

3

1 reference

11 February 2018

Alessandro Tessitore

Alessandro Tessitore

4

0 references

Francesca Morgante

Francesca Morgante

10

0 references

Roberto Ceravolo

Roberto Ceravolo

7

0 references

Fabrizio Stocchi

Fabrizio Stocchi

6

0 references

Carlo Caltagirone

8

Carlo Caltagirone

1 reference

11 February 2018

2

Giuseppe Meco

1 reference

11 February 2018

9

Mauro Silvestrini

1 reference

11 February 2018

author name string

Mariangela Pierantozzi

5

1 reference

11 February 2018

Stefano Ruggieri

11

1 reference

11 February 2018

Laura Avanzino

12

1 reference

11 February 2018

Michele Guadagna

13

1 reference

11 February 2018

Grazia Dell'Agnello

14

1 reference

11 February 2018

Andrea Rossi

15

1 reference

11 February 2018

Riccardo Spezia

16

1 reference

11 February 2018

Michele Mancini

17

1 reference

11 February 2018

language of work or name

English

0 references

publication date

1 November 2012

1 reference

11 February 2018

Expert Opinion on Pharmacotherapy

published in

1 reference

11 February 2018

volume

13

1 reference

11 February 2018

issue

16

1 reference

11 February 2018

page(s)

2269-2280

1 reference

11 February 2018

Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson's disease

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.736490

A systematic review of prevalence studies of depression in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.736490

Depression in Parkinson's disease -- a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.736490

The quality of life in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.736490

What contributes to quality of life in patients with Parkinson's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.736490

Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.736490

Depression in Parkinson's disease. Pharmacological characteristics and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.736490

Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.736490

Current approaches to management of depression in Parkinson's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.736490

Selective serotonin-reuptake inhibitor-induced movement disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.736490

A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.736490

Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.736490

Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.736490

Duloxetine in acute major depression: review of comparisons to placebo and standard antidepressants using dissimilar methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.736490

Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.736490

The impact of depressive symptoms in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.736490

SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.736490

Antidepressant studies in Parkinson's disease: a review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.736490

Cardiovascular autonomic dysfunction in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.736490

Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.736490

Impact of psychiatric symptoms and sleep disorders on the quality of life of patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.736490

Assessment of sleep and sleepiness in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.736490

The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.736490

Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.736490

Clinical consequences of initial duloxetine dosing strategies: Comparison of 30 and 60 mg QD starting doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.736490

Parkinsonism: onset, progression, and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.736490

A rating scale for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.736490

An Inventory for Measuring Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.736490

The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.736490

10.1517/14656566.2012.736490

21 January 2018

Identifiers

DOI

1 reference

11 February 2018

release_jsvfc7by4bhhxbrvu6lblz6wy4

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/jsvfc7by4bhhxbrvu6lblz6wy4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

11 February 2018